王新龙

摘  要：目的  探究与分析依巴斯汀联合布地奈德治疗变应性鼻炎（AR）的疗效及对炎性因子及T淋巴细胞亚群的影响。方法  选取菏泽市中医医院自2018年5月～2020年5月收治的AR患者120例，采取随机数表法分为单药组与联合组，每组60例，单药组仅给予布地奈德喷剂治疗，联合组在单药组基础上加用依巴斯汀治疗，对比两组临床疗效、炎性因子、T淋巴细胞亚群水平。结果  联合组临床总有效率高于单药组，差异有统计学意义（P<0.05）。联合组治疗后与单药组治疗后相比血清IL-4、IL-6及IL-10水平均降低，差异有统计学意义（P<0.05）。联合组治疗后与单药组治疗后相比CD3+较高、CD4+较高、CD8+较低、CD4+/CD8+较高，差异有统计学意义（P<0.05）。结论  依巴斯汀联合布地奈德治疗AR可有效改善患者的临床症状及体征，减轻炎性反应，调节细胞免疫功能。

关键词：依巴斯汀;布地奈德;AR;疗效;炎性因子;T淋巴细胞亚群

中图分类号：R765    文献标识码：A    文章编号：1009-8011（2021）-13-0003-03

Ebastine combined with budesonide in the treatment of allergic rhinitis （AR） and its effect on inflammatory factors and T lymphocyte subsets

WANG Xin-long

（Department of Otorhinolaryngology， Heze Hospital of Traditional Chinese Medicine， Shandong Heze， 274000， China）

Abstract： Objective  To explore and analyze the efficacy of ebastine combined with budesonide in the treatment of allergic rhinitis（AR）， and its influence on inflammatory factors and T lymphocyte subsets. Methods  A total of 120 AR patients admitted to our hospital from May 2018 to May 2020 were selected and divided into single-drug group and combination group by random number table， 60 cases in each group， and only budesonide in the single-drug group. For spray treatment， the combination group was treated with ebastine on the basis of the single-drug group， and the clinical efficacy， inflammatory factors， and T lymphocyte subgroup levels were compared between the two groups. Results  The total clinical effective rate of the combined group was higher than that of the single-drug group， with statistical significance（P<0.05）. Serum levels of IL-4， IL-6 and IL-10 in the combination group were significantly lower than those in the single-agent group after treatment， with statistical significance（P<0.05）. Compared with the single-agent group after treatment， the combination group had higher CD3+， higher CD4+， lower CD8+， higher CD4+/CD8+， with statistical significance（P<0.05）. Conclusion  Ebastine combined with budesonide in the treatment of AR can effectively improve the clinical symptoms and signs of patients， reduce inflammatory reactions， and regulate cellular immune function. There are no obvious adverse reactions during the treatment period and the safety is high.

Keywords： Ebastine; Budesonide; AR; Efficacy; Inflammatory factors; T lymphocyte subsets

變应性鼻炎（AR）作为一种发病率较高的耳鼻喉科常见疾病，病程较强且难以彻底治愈，其主要是指当机体与致敏原密切接触之后，在多种炎性细胞及因子的作用及共同参与之下，由IgE所介导的引起鼻黏膜慢性炎症反应性疾病[1]。该病临床上主要表现出不同程度的发作性喷嚏、清水样鼻涕、鼻部瘙痒等症状，严重时可随着疾病的进展引起阻塞性睡眠呼吸障碍，对患者的日常生活质量造成了较大影响[2]。结合变应性鼻炎的发生发展机制，临床认为治疗该病时可以抗组胺类或（和）糖皮质激素类药物为主，不过单独使用其中一类药物的治疗效果较为一般。现将菏泽市中医医院于2018年5月～2020年5月收治的120例AR患者作为研究对象，对依巴斯汀联合布地奈德方案应用于AR的治疗过程中，旨在取得更好的效果，结果报告如下。

1  资料与方法

1.1  一般资料

选取菏泽市中医医院自2018年5月～2020年5月收治的120例AR患者，采取随机数表法分为单药组与联合组，各60例。……